Vyteris, Inc. Close to Signing $20 Million Deal for Product to Treat Female Infertility

Published: Aug 06, 2010

LOS ANGELES, CA--(Marketwire - 08/05/10) - Two weeks ago, Vyteris, Inc. (OTC.BB:VYTR - News), the manufacturer of the first FDA-approved active patch transdermal drug delivery system announced the appointment of four new members to its Scientific Advisory Board. The news went mostly unnoticed, but it could point to some significant catalysts and developments for a company that recently found itself on the ropes.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector, has issued a trade alert for Vyteris after reporting that finance industry sources have indicated that Phase 2 data for the company's innovative product to treat female infertility "is very strong" and that the company is close to signing a deal worth $20 million upfront which is also loaded with not only milestones, but also royalties.

VYTR had previously partnered with Ferring Pharmaceuticals to develop the product which would mimic the female body's natural rhythms of hormonal secretions. The product would make it possible to administer a peptide without needles, and was being designed to deliver multiple transdermal pulses automatically, around the clock with as little as two 12-hour patches per day. In addition to the less painful therapy, there were also potential benefits that would possibly reduce the likelihood of multiple births.

However, in December of 2009, Vyteris received notice from Ferring that they were terminating a License and Development Agreement, dated September 30, 2004. This rocked the stability of the company and shares saw a rocky ride from highs of $1.40 to lows of $.11.

The company has approximately 65 million outstanding shares, but only about 5 million are currently in the float. Since the rest are tightly held, the stock may be poised to climb higher on news.

The trade alert and full report is available now at BioMedReports.Com.

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:


About BioMedReports.Com BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to http://BioMedReports.com Contact:

Media Contact: Mary Davila Assistant Editor BioMedReports.Com e-mail: Email Contact Tel: +1 323 472 4480 Fax: +1 888 210 3556

Back to news